The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells.

Autor:	Baev DV; Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Biosciences, Dangan, Galway, Ireland., Krawczyk J; Department of Hematology, University Hospital Galway, Newcastle Road, Galway, Ireland., O׳Dwyer M; Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Biosciences, Dangan, Galway, Ireland ; Department of Hematology, University Hospital Galway, Newcastle Road, Galway, Ireland., Szegezdi E; Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Biosciences, Dangan, Galway, Ireland.
Jazyk:	angličtina
Zdroj:	Leukemia research reports [Leuk Res Rep] 2014 Sep 01; Vol. 3 (2), pp. 79-82. Date of Electronic Publication: 2014 Sep 01 (Print Publication: 2014).
DOI:	10.1016/j.lrr.2014.06.001
Abstrakt:	The anti-apoptotic proteins Bcl-XL and Bcl-2 are abundantly expressed in hematopoietic stem cells and/or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for its ability to eradicate putative leukemic stem cells. ABT-737 demonstrated potent cytotoxic effects in all patient samples tested. The efficacy of ABT-737 against AML blasts and the primitive CD34(+)/CD38(-) population was equal and independent of sensitivity to cytarabine/daunorubicin. These results, together with previously reported synergistic effects of ABT-737 with chemotherapeutics make BH3-mimetics promising candidates for future AML treatment regimens.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu